A sabotaged mitochondrial cleanup chain drives blinding retinal scarring — and blocking it worked in mice
·Tip: press play, then lock your phone or switch apps — the article keeps reading.
Age-related macular degeneration steals central vision from millions of older adults — and its hardest stage, subretinal fibrosis, has no approved treatment at all. A new study in GeroScience now traces that irreversible scarring to a broken mitochondrial cleanup chain: a little-studied protein called LAPTM5 accumulates in the aging retina's support cells, dismantles the machinery that clears damaged mitochondria, and the leaked mitochondrial DNA triggers an immune alarm that ends in scar tissue.
The cascade, step by step
The team — led by Xiaowei Yang, Shenglai Zhang, and Yan Wang of Nantong University — found LAPTM5 elevated in human AMD specimens and in an aged mouse model, tracking with senescence and fibrosis markers. Gain- and loss-of-function experiments then proved it was a driver, not a bystander: raising LAPTM5 pushed retinal pigment epithelium cells into senescence, while lowering it blunted the program.
The mechanism is a chain of dominoes. LAPTM5 grabs WWP2 — the ligase that tags damaged mitochondria for disposal — and sends it to be destroyed. Without its tags, the autophagy receptor optineurin can't recognize broken mitochondria, so mitophagy stalls and damaged mitochondria pile up. Their membranes go leaky, mitochondrial DNA spills into the cytoplasm, and the cell's cGAS-STING alarm system — which mistakes the DNA for a virus — fires a sustained inflammatory response that drives neighboring cells to build scar tissue.
Two ways to block it — both worked
This is where it gets exciting for patients. Using an AAV vector to knock down Laptm5 specifically in the retina of aged mice, the team markedly reduced subretinal fibrotic lesions. Separately, the STING inhibitor H-151 — blocking the inflammatory arm of the cascade — significantly slowed the scarring process. Two independent entry points into the same pathway, both validated.
The honest limits: the work leaned on a D-galactose-induced aging model, which accelerates some aging features but doesn't fully reproduce decades of human AMD, and some of the downstream steps from inflammation to scar remain partly inferential. Gene delivery to the retina is also practically challenging. But a disease stage with zero treatments now has a defined, druggable cascade — and that transforms the search for a therapy.
Where the evidence stands
- Established: Subretinal fibrosis in age-related macular degeneration has no approved therapy that reverses or reliably halts it; mitophagy clears damaged mitochondria.
- Preliminary: The LAPTM5→WWP2→OPTN→mitophagy→cGAS-STING cascade as a driver of RPE senescence and scarring — demonstrated in cells and a D-galactose aging mouse model; knockdown and STING inhibition reduced lesions.
- Absent: Human data; whether targeting LAPTM5 or STING is safe and effective in people; the paracrine steps linking the inflammatory signals to scar formation remain partly inferential.